Literature DB >> 27466344

Reversal of Pathologic Lipid Accumulation in NPC1-Deficient Neurons by Drug-Promoted Release of LAMP1-Coated Lamellar Inclusions.

Valérie Demais1, Amélie Barthélémy2, Martine Perraut2, Nicole Ungerer2, Céline Keime3, Sophie Reibel4, Frank W Pfrieger5.   

Abstract

UNLABELLED: Aging and pathologic conditions cause intracellular aggregation of macromolecules and the dysfunction and degeneration of neurons, but the mechanisms are largely unknown. Prime examples are lysosomal storage disorders such as Niemann-Pick type C (NPC) disease, where defects in the endosomal-lysosomal protein NPC1 or NPC2 cause intracellular accumulation of unesterified cholesterol and other lipids leading to neurodegeneration and fatal neurovisceral symptoms. Here, we investigated the impact of NPC1 deficiency on rodent neurons using pharmacologic and genetic models of the disease. Improved ultrastructural detection of lipids and correlative light and electron microscopy identified lamellar inclusions as the subcellular site of cholesterol accumulation in neurons with impaired NPC1 activity. Immunogold labeling combined with transmission electron microscopy revealed the presence of CD63 on internal lamellae and of LAMP1 on the membrane surrounding the inclusions, indicating their origins from intraluminal vesicles of late endosomes and of a lysosomal compartment, respectively. Lamellar inclusions contained cell-intrinsic cholesterol and surface-labeled GM1, indicating the incorporation of plasma membrane components. Scanning electron microscopy revealed that the therapeutic drug candidate β-cyclodextrin induces the subplasmalemmal location of lamellar inclusions and their subsequent release to the extracellular space. In parallel, β-cyclodextrin mediated the NPC1-independent redistribution of cholesterol within neurons and thereby abolished a deleterious cycle of enhanced cholesterol synthesis and its intracellular accumulation, which was indicated by neuron-specific transcript analysis. Our study provides new mechanistic insight into the pathologic aggregation of macromolecules in neurons and suggests exocytosis as cellular target for its therapeutic reversal. SIGNIFICANCE STATEMENT: Many neurodegenerative diseases involve pathologic accumulation of molecules within neurons, but the subcellular location and the cellular impact are often unknown and therapeutic approaches lacking. We investigated these questions in the lysosomal storage disorder Niemann-Pick type C (NPC), where a defect in intracellular cholesterol transport causes loss of neurons and fatal neurovisceral symptoms. Here, we identify lamellar inclusions as the subcellular site of lipid accumulation in neurons, we uncover a vicious cycle of cholesterol synthesis and accretion, which may cause gradual neurodegeneration, and we reveal how β-cyclodextrin, a potential therapeutic drug, reverts these changes. Our study provides new mechanistic insight in NPC disease and uncovers new targets for therapeutic approaches.
Copyright © 2016 the authors 0270-6474/16/368013-14$15.00/0.

Entities:  

Keywords:  cholesterol metabolism; electron microscopy; exocytosis; inborn errors metabolism; lysosome; transcript profiling

Mesh:

Substances:

Year:  2016        PMID: 27466344      PMCID: PMC6601882          DOI: 10.1523/JNEUROSCI.0900-16.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  11 in total

1.  Monitoring the itinerary of lysosomal cholesterol in Niemann-Pick Type C1-deficient cells after cyclodextrin treatment.

Authors:  McKenna Feltes; Sarah E Gale; Samantha Moores; Daniel S Ory; Jean E Schaffer
Journal:  J Lipid Res       Date:  2020-01-27       Impact factor: 5.922

Review 2.  Cholesterol and the journey of extracellular vesicles.

Authors:  Frank W Pfrieger; Nicolas Vitale
Journal:  J Lipid Res       Date:  2018-04-20       Impact factor: 5.922

3.  A quantitative yeast aging proteomics analysis reveals novel aging regulators.

Authors:  Yu Sun; Ruofan Yu; Hao-Bo Guo; Hong Qin; Weiwei Dang
Journal:  Geroscience       Date:  2021-07-09       Impact factor: 7.713

Review 4.  Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases.

Authors:  Jacob M Favret; Nadav I Weinstock; M Laura Feltri; Daesung Shin
Journal:  Front Mol Biosci       Date:  2020-04-15

Review 5.  Understanding and Treating Niemann-Pick Type C Disease: Models Matter.

Authors:  Valentina Pallottini; Frank W Pfrieger
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

6.  Correlative light and electron microscopy suggests that mutant huntingtin dysregulates the endolysosomal pathway in presymptomatic Huntington's disease.

Authors:  Gillian P Bates; Helen R Saibil; Ya Zhou; Thomas R Peskett; Christian Landles; John B Warner; Kirupa Sathasivam; Edward J Smith; Shu Chen; Ronald Wetzel; Hilal A Lashuel
Journal:  Acta Neuropathol Commun       Date:  2021-04-14       Impact factor: 7.801

7.  A human iPSC-derived inducible neuronal model of Niemann-Pick disease, type C1.

Authors:  Anika V Prabhu; Insung Kang; Raffaella De Pace; Christopher A Wassif; Hideji Fujiwara; Pamela Kell; Xuntian Jiang; Daniel S Ory; Juan S Bonifacino; Michael E Ward; Forbes D Porter
Journal:  BMC Biol       Date:  2021-10-01       Impact factor: 7.431

8.  Assessment of FDA-Approved Drugs as a Therapeutic Approach for Niemann-Pick Disease Type C1 Using Patient-Specific iPSC-Based Model Systems.

Authors:  Christin Völkner; Supansa Pantoom; Maik Liedtke; Jan Lukas; Andreas Hermann; Moritz J Frech
Journal:  Cells       Date:  2022-01-18       Impact factor: 6.600

9.  Transcriptome of HPβCD-treated Niemann-Pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics.

Authors:  Jorge L Rodriguez-Gil; Laura L Baxter; Dawn E Watkins-Chow; Nicholas L Johnson; Cristin D Davidson; Steven R Carlson; Arturo A Incao; Kerri L Wallom; Nicole Y Farhat; Frances M Platt; Ryan K Dale; Forbes D Porter; William J Pavan
Journal:  Hum Mol Genet       Date:  2021-11-30       Impact factor: 5.121

10.  Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann-Pick diseases.

Authors:  Mark L Schultz; Maria V Fawaz; Ruth D Azaria; Todd C Hollon; Elaine A Liu; Thaddeus J Kunkel; Troy A Halseth; Kelsey L Krus; Ran Ming; Emily E Morin; Hayley S McLoughlin; David D Bushart; Henry L Paulson; Vikram G Shakkottai; Daniel A Orringer; Anna S Schwendeman; Andrew P Lieberman
Journal:  BMC Med       Date:  2019-11-11       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.